NCT03322436 (HeartLinc) is a clinical trial of HeartLinc kit in AMI Patients, sponsored by Firalis SA.

Who is sponsoring NCT03322436?

NCT03322436 is sponsored by Firalis SA.

What drugs are being tested in NCT03322436?

Interventions in NCT03322436: HeartLinc kit.

What condition does NCT03322436 study?

NCT03322436 studies AMI Patients.

Is NCT03322436 still recruiting?

NCT03322436 is currently completed. Last updated 23 May 2024.

Last reviewed 2024-05-23 · How we verify

NCT03322436: HeartLinc

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HeartLinc, a Study With AMI Patients Undergoing PCI

Completed Last updated 23 May 2024

What this trial tests

trial testing HeartLinc kit in AMI Patients in 240 participants. Completed in 31 October 2022.

Timeline

13 March 2018

Primary endpoint
30 July 2022

31 October 2022

Quick facts

Lead sponsor	Firalis SA
Status	Completed
Study type	OBSERVATIONAL
Enrollment	240
Start date	13 March 2018
Primary completion	30 July 2022
Estimated completion	31 October 2022
Sites	2 locations across France, South Korea

Drugs / interventions tested

HeartLinc kit

Conditions studied

AMI Patients — all drugs for AMI Patients →

Sponsor

Firalis SA

Who can join

18 and older, any sex, with AMI Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

HeartLinc is a non-interventional patient study to demonstrate medical utility of the lncRNA to predict HF in AMI patients. 300 patients are expected to be recruited.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Firalis SA trials

Trials by the same sponsor.

NCT06515821 — Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods · recruiting
NCT06432192 — A Prospective, Monocentric Clinical Study for the Validation of in Vitro Diagnostic Tests Developed by Firalis · completed
NCT04583319 — Validation of a Rapid, Non-invasive Point-of-care IVD Test for Diagnosis of SARS-COV-2 (COVID-19) Infection · completed
NCT03038360 — Prospective Study With AMI Patients Undergoing PCI · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03322436 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Firalis SA
Last refreshed: 23 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03322436.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing